Skip to Main Content

Paper Details

Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistance.
bioRxiv
6
2023
BI-3406, CRC, EGFR, KRAS, KRAS-driven cancers, KRAS-mutated tumors, KRASi, MAPK, RAS, SHP2, SOS1, adagrasib, anti-, colorectal cancer, lung cancer, tumor
Author NameAffiliation
Christopher A BristowThe University of Texas MD Anderson Cancer Center
Christopher A BristowThe University of Texas MD Anderson Cancer Center
Daniel Gerlach
Scott KopetzThe University of Texas MD Anderson Cancer Center
Timothy P HeffernanThe University of Texas MD Anderson Cancer Center
  • 1 - 5

Datasets

Release 1.2